

Matteo Ruggeri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5126021/publications.pdf>

Version: 2024-02-01

59
papers

1,410
citations

471061

17
h-index

344852

36
g-index

62
all docs

62
docs citations

62
times ranked

2590
citing authors

#	ARTICLE	IF	CITATIONS
1	Telemedicine as technoinnovation to tackle COVID-19: A bibliometric analysis. <i>Technovation</i> , 2023, 120, 102417.	4.2	23
2	On the Frontlineâ€”A bibliometric Study on Sustainability, Development, Coronaviruses, and COVID-19. <i>Environmental Science and Pollution Research</i> , 2023, 30, 42983-42999.	2.7	13
3	The costs of treatment resistant depression: evidence from a survey among Italian patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 437-444.	0.7	5
4	The transcatheter aortic valve implantation: an assessment of the generalizability of the economic evidences following a systematic review. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, e27.	0.2	0
5	Estimation Model for Healthcare Costs and Intensive Care Units Access for Covid-19 Patients and Evaluation of the Effects of Remdesivir in the Portuguese Context: Hypothetical Study. <i>Clinical Drug Investigation</i> , 2022, 42, 345-354.	1.1	4
6	Is risk attitude toward health outcomes context driven?. <i>Quality and Quantity</i> , 2021, 55, 63-77.	2.0	1
7	Burden of COVID-19 on Italian Internal Medicine Wards: Delphi, SWOT, and Performance Analysis after Two Pandemic Waves in the Local Health Authority â€”Roma 6â€”Hospital Structures. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5999.	1.2	11
8	Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain. <i>Clinical Drug Investigation</i> , 2021, 41, 875-883.	1.1	4
9	Multiâ€”Criteriaâ€”Decisionâ€”Analysis (MCDA) for the Horizon Scanning of Health Innovations an Application to COVID 19 Emergency. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7823.	1.2	13
10	The Determinants of Out-of-Pocket Expenditure in IBD Italian Patients. Results from the AMICI Survey. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8156.	1.2	4
11	Estimating the fiscal impact of three vaccination strategies in Italy. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 133-138.	0.2	8
12	Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review. <i>Pharmacoeconomics</i> , 2020, 38, 473-484.	1.7	5
13	Economic evaluation of colorectal cancer screening programs: Affordability for the health service. <i>Journal of Medical Screening</i> , 2020, 27, 186-193.	1.1	3
14	Model for estimating the healthcare costs and capacity of intensive care units in Italy in the treatment of patients with COVID-19: remdesivir impact assessment. <i>AboutOpen</i> , 2020, 7, 95-102.	0.2	8
15	A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer. <i>Global & Regional Health Technology Assessment</i> , 2020, 7, 1-8.	0.2	0
16	Setting research priorities in the field of emergency management: which piece of information are you willing to pay more?. <i>Quality and Quantity</i> , 2019, 53, 2103-2115.	2.0	1
17	Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort. <i>Value in Health</i> , 2018, 21, 783-791.	0.1	10
18	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429.	6.3	345

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 711-722.	1.0	15
20	What are the motivating and hindering factors for health professionals to undertake new roles in hospitals? A study among physicians, nurses and managers looking at breast cancer and acute myocardial infarction care in nine countries. <i>Health Policy</i> , 2018, 122, 1118-1125.	1.4	12
21	New professional roles and patient satisfaction: Evidence from a European survey along three clinical pathways. <i>Health Policy</i> , 2018, 122, 1078-1084.	1.4	13
22	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1079-1088.	0.6	50
23	Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy. <i>Journal of Medical Economics</i> , 2018, 21, 902-911.	1.0	23
24	Artificial neural networks and their potentialities in analyzing budget health data: an application for Italy of what-if theory. <i>Quality and Quantity</i> , 2017, 51, 1261-1276.	2.0	2
25	Preventing mobility disability in Europe: a health economics perspective from the SPRINTT study. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 75-79.	1.4	5
26	Does regional belonging explain the similarities in the expenditure determinants of Italian healthcare deliveries?. <i>Economic Analysis and Policy</i> , 2017, 55, 47-56.	3.2	0
27	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	3.6	25
28	Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza. <i>Global & Regional Health Technology Assessment</i> , 2017, 4, grhta.5000251.	0.2	0
29	COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 233-240.	0.2	10
30	Use of robot-specific resources and operating room times: the case of Telelap AlfaX robotic hysterectomy. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2016, 12, 613-619.	1.2	19
31	Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. <i>Blood Transfusion</i> , 2016, 14, 287-386.	0.3	17
32	Is solvent/detergent plasma better than standard fresh-frozen plasma? A systematic review and an expert consensus document. <i>Blood Transfusion</i> , 2016, 14, 277-286.	0.3	24
33	Evolution of the Healthcare Expenditure in Italy and Effects of Fingolimod Increased Prescribing in Second Line Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Global & Regional Health Technology Assessment</i> , 2016, 3, GRHTA.5000232.	0.2	0
34	Cost-Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 947-955.	1.5	5
35	Economic evaluation of screening programs for hepatitis C virus infection: evidence from literature. <i>Risk Management and Healthcare Policy</i> , 2015, 8, 45.	1.2	18
36	Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs. <i>ClinicoEconomics and Outcomes Research</i> , 2015, 7, 575.	0.7	13

#	ARTICLE	IF	CITATIONS
37	Economic assessment of eltrombopag in the treatment of thrombocytopenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 713-720.	0.7	4
38	Investigating the Generalizability of Economic Evaluations Conducted in Italy: A Critical Review. Value in Health, 2015, 18, 709-720.	0.1	14
39	Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology, 2015, 28, 593-602.	0.9	11
40	Do Probability and Certainty Equivalent Techniques Lead to Inconsistent Results? Evidence from Gambles Involving Life-Years and Quality of Life. Value in Health, 2015, 18, 413-424.	0.1	2
41	Comparing tapentadol to oxycodone/naloxone combination: imagining castles in the air while building sandcastles! Re: Coluzzi F, Ruggeri M. Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Curr Med Res Opin 2014;30:1139-51. Current Medical Research and Opinion, 2015, 31, 339-342.	0.9	2
42	A Pharmacoeconomic Analysis of Phosphate Binders Cost-Effectiveness in the RISCAVID Study. Blood Purification, 2015, 39, 174-180.	0.9	4
43	The minimum clinically important difference for EQ-5D index: a critical review. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 221-233.	0.7	217
44	Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. Current Medical Research and Opinion, 2014, 30, 1139-1151.	0.9	33
45	Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 459-464.	0.7	9
46	Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study. Blood Purification, 2014, 37, 316-324.	0.9	11
47	Cost-Effectiveness Studies in HIV Treatment with Lopinavir/Ritonavir: A Review. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.5000184.	0.2	0
48	Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults. Clinical Drug Investigation, 2013, 33, 343-349.	1.1	22
49	Economic Assessment of an Anti-HCV Screening Program in Italy. Value in Health, 2013, 16, 965-972.	0.1	28
50	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. Journal of Hepatology, 2013, 59, 658-666.	1.8	41
51	THE HARMONIC STUDY: COST-EFFECTIVENESS EVALUATION OF THE USE OF THE ULTRASONIC SCALPEL IN TOTAL THYROIDECTOMY. International Journal of Technology Assessment in Health Care, 2012, 28, 259-264.	0.2	13
52	Is risk attitude really specific within the health context domain? Further evidence from an Italian survey using probability equivalent technique and face-to-face interviews. Health, Risk and Society, 2012, 14, 655-666.	0.9	5
53	Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. Risk Management and Healthcare Policy, 2012, 5, 49.	1.2	33
54	The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy, 2011, 102, 72-80.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Extending influenza vaccination to individuals aged 50–64: A budget impact analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 288-293.	0.2	13
56	Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4085-4091.	1.4	185
57	Is risk attitude outcome specific within the health domain?. <i>Journal of Health Economics</i> , 2008, 27, 706-717.	1.3	36
58	Clinical and Economic Benefits of a New Paradigm of HCV Diagnosis and Treatment. <i>Global & Regional Health Technology Assessment</i> , 0, 8, 58-66.	0.2	0
59	Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study. <i>Clinical Drug Investigation</i> , 0, , .	1.1	4